Christian Mandl, Ph.d, M.d.
SVP, RNA Technologies
immunology
ImmunoGen
Malta
Biography
Christian W. Mandl is Senior Vice President of RNA Technologies and Boston Site Head at Vir. Previously he was the Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines. In this role, he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying RNA technology (SAM®), which he initiated in 2008 inspired by his previous academic research.
Research Interest
Christian W. Mandl is Senior Vice President of RNA Technologies and Boston Site Head at Vir. Previously he was the Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines. In this role, he led a global team of more than 300 discovery and clinical researchers developing a broad range of viral and bacterial vaccines, adjuvants and delivery platforms including the self-amplifying RNA technology (SAM®), which he initiated in 2008 inspired by his previous academic research.
